Plenty of eye-opening material was published this August! Among this month’s highlights are a small molecule with twice-a-year dosing from Gilead, a non-classical C-H—O hydrogen-bonding kinase inhibitor from Pfizer, an E1 ligase inhibitor with a cool substrate-assisted covalent mechanism from Takeda, and some STING agonists with well-tolerated oral activity and fascinating mechanisms from Merck and TSRI/Calibr. Links to the articles and more discussion on specific molecules below.